Nevertheless, several meta-analyses of CVOTs showed that GLP-1 RA decreased MACE risk by 14–16%, and, as a class, they did significantly decrease hazard ratios for individual events, including death from CV causes, fatal or non-fatal stroke, fatal or non-fatal myocardial infarction, and all-cause mortality [12–15]. This evidence concerns the gene GLP1R and myocardial infarction.